Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Return on Capital Employed (2021 - 2024)

Immuneering has reported Return on Capital Employed over the past 4 years, most recently at 0.94% for Q3 2024.

  • Quarterly results put Return on Capital Employed at 0.94% for Q3 2024, down 44.0% from a year ago — trailing twelve months through Sep 2024 was 0.94% (down 44.0% YoY), and the annual figure for FY2023 was 0.56%, down 18.0%.
  • Return on Capital Employed for Q3 2024 was 0.94% at Immuneering, down from 0.8% in the prior quarter.
  • Over the last five years, Return on Capital Employed for IMRX hit a ceiling of 0.21% in Q4 2021 and a floor of 0.94% in Q3 2024.
  • Median Return on Capital Employed over the past 4 years was 0.49% (2023), compared with a mean of 0.49%.
  • Biggest five-year swings in Return on Capital Employed: dropped -10bps in 2022 and later tumbled -44bps in 2024.
  • Immuneering's Return on Capital Employed stood at 0.21% in 2021, then tumbled by -103bps to 0.43% in 2022, then crashed by -35bps to 0.58% in 2023, then plummeted by -61bps to 0.94% in 2024.
  • The last three reported values for Return on Capital Employed were 0.94% (Q3 2024), 0.8% (Q2 2024), and 0.66% (Q1 2024) per Business Quant data.